Rink Amide Resin |
Katalog-Nr.GA11149 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 13653-84-4
Sample solution is provided at 25 µL, 10mM.
Rink resin is originally developed for SPS of peptide amides. Now the scope of its application is extended from carboxylic amides to the immobilization of amines, substituted amides. Libaries of primary amines have been synthesized by the treatment of Rink amine resin with aldehyde to form aldimines, which are subsequently reacted with Grignard reagents or lithium reagents to yield amines that are not commercially available. These amines are released from resin by treatmnet with TFA-water-DCM (5:5:90) for 5 h at room temperature. N-Substituted amides are obtained by reducing the above-mentioned aldimines with Na(CN)BH3 to the corresponding amines, followed by acylation with acid chlorides or symmetrical anhydrides. The produts are cleaved with TFA-water-DCM (5:1:94) for 20 min at room temperature. Direct functionalization of Rink amide resin with nucleophiles has also been reported. The Fmoc protecting group can be readly removed with 20% piperidine in DMF prior to the above manipulation.
Rink amide resin: 4-(2',4'-Dimethoxyphenyl-Fmoc-aminomethyl-phenoxy-acetamido- norleucylaminomethyl resin; Substitution: 0.4 - 0.8 mmole/g resin; Bead size 100- 200 mesh (polystyrene- 1% DVB)
Structure: Application: Li et al reported a simple, clean, high yielding and linker-free method for the synthesis of disubstituted guanidines by using Rink amide resin as an amine component [1]. Decomposition of the resin linkers during TFA cleavage of the peptides in the Fmoc strategy leads to alkylation of sensitive amino acids. The C-terminal amide alkylation, reported for the first time, is shown to be a major problem in peptide amides synthesized on the Rink amide resin. This side reaction occurs as a result of the Rink amide linker decomposition under TFA treatment of the peptide resin. The use of 1,3-dimethoxybenzene in a cleavage cocktail prevents almost quantitatively formation of C-terminal N-alkylated peptide amides. Oxidized by-product in the tested Cys- and Met-containing peptides were not observed, even if thiols were not used in the cleavage mixture[2].
Reference:
[1] Min Li, Lawrence J. Wilson and David E. Portlock. A simple solid-phase synthesis of disubstituted guanidines using Rink amide resin as an amine component. Tetrahedron Letters 42 (2001) 2273–2275
[2] Stathopoulos P, Papas S, Tsikaris V. C-terminal N-alkylated peptide amides resulting from the linker decomposition of the Rink amide resin: a new cleavage mixture prevents their formation. J Pept Sci. 2006;12(3):227-32.
Cas No. | 13653-84-4 | SDF | |
Chemical Name | [1,1':4',1''-terphenyl]-4,4''-dicarboxylic acid | ||
Canonical SMILES | O=C(O)C1=CC=C(C2=CC=C(C3=CC=C(C(O)=O)C=C3)C=C2)C=C1 | ||
Formula | C20H14O4 | M.Wt | 318.32 |
Löslichkeit | Storage | ||
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.1415 mL | 15.7075 mL | 31.4149 mL |
5 mM | 0.6283 mL | 3.1415 mL | 6.283 mL |
10 mM | 0.3141 mL | 1.5707 mL | 3.1415 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *